Rachel Engelberg, MD
Urology · Homewood, ALNPI 1255793923
Payments from drug & device makers
What this record shows
This record is dominated by grants: $50,000 of the $60,799 with a category attached, or 82.2%. Boston Scientific accounts for 88.9% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2021 at $52,109 and has fallen 98.2% since, to $939 in 2025. Among urology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 143 payments — averaging $425.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$54K
- Coloplast$6K
- Endo Pharmaceuticals Inc.$223
- Bayer$151
- Johnson & Johnson$110
- Laborie Medical Technologies Corp.$108
- plus $548 from 15 others
What the payments were for
- Consulting fees$1650%
- Grants$50,00082%
- Travel & lodging$5,5089%
- Food & beverage$5,0358%
- Education$910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 49 | $54,071 |
| Coloplast | 60 | $5,588 |
| Endo Pharmaceuticals Inc. | 5 | $223 |
| Bayer | 1 | $151 |
| Johnson & Johnson | 4 | $110 |
| Laborie Medical Technologies Corp. | 1 | $108 |
| Tolmar, Inc. | 3 | $82 |
| Urovant Sciences Inc | 4 | $63 |
| Astellas Pharma US Inc | 2 | $56 |
| Sumitomo Pharma America, Inc. | 2 | $45 |
| Astellas Pharma Global Development | 1 | $37 |
| Medtronic | 2 | $34 |
| AbbVie | 1 | $32 |
| AstraZeneca | 1 | $29 |
| Procept Biorobotics Corporation | 1 | $27 |
| Urogen Pharma, Inc. | 1 | $25 |
| Telix Pharmaceuticals | 1 | $25 |
| Ferring Pharmaceuticals Inc. | 1 | $25 |
| Progenics Pharmaceuticals, Inc. | 1 | $23 |
| Pfizer | 1 | $23 |
| Tolmar Pharmaceuticals, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL ERECTILE DYSFUNCTION$50,259
- TITAN$3,910
- AMS 700 CXR RTE KIT$1,921
- Nubeqa$151
- GENERAL KIDNEY STONE DISEASE$151
- AMS 700$127
- XIAFLEX$123
- GENESIS$112
- ALTIS$110
- Optilume BPH Drug Coated Balloon Catheter$108
How this compares
$60,799 in reported general payments places this provider in the 95th percentile of 179 urology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 95 | $73,194 |
| GemtesaVibegron | 68 | $62,718 |
| Estradiol | 67 | $3,470 |
| Oxybutynin Chloride ErOxybutynin Chloride | 74 | $2,395 |
| Tamsulosin Hcl | 156 | $2,369 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 83 | $2,013 |
| Cefpodoxime Proxetil | 50 | $1,204 |
| Testosterone Cypionate | 32 | $954 |
| Finasteride | 51 | $849 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 42 | $613 |
| Oxybutynin Chloride | 29 | $378 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 69 | $302 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 24 | $194 |
| Tramadol Hcl | 31 | $78 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $56 | $73,19495 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $45 | $62,71868 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 179 urology providers in Alabama.
Other urology in Homewood
- Brian ChristineHomewood$215K
- Vincent BivinsHomewood$117K
- Rupa KitchensHomewood$14K
- Jared CoxHomewood$12K
- Brian WadeHomewood$9K
- Donald BraggHomewood$8K
- Tyler PostonHomewood$6K
- Paula RookisHomewood$6K
- Leon HamrickHomewood$5K
- Thomas ChiBirmingham$463K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.